Potential for a theranostic approach targeting cancer associated fibroblasts

Patrick Conen; Kai J. Dautzenberg; Felix M. Mottaghy

doi:10.1016/B978-0-12-822960-6.00039-9

Potential for a theranostic approach targeting cancer associated fibroblasts

Patrick Conen, Kai J. Dautzenberg, Felix M. Mottaghy

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic

Abstract

In recent years, targeting cancer associated fibroblasts (CAFs) for efficient therapy approaches has been evaluated. The fibroblast-activating protein (FAP) has received special attention within nuclear medicine approaches due to the development of a successful radiolabeled FAP-inhibitor. This short chapter reviews briefly the background of this approach and gives some insight into potential theranostic applications of the newly developed FAPI ligands.

Original language	English
Title of host publication	Nuclear Medicine and Molecular Imaging: Volume 1-4
Publisher	Elsevier
Pages	353-356
Number of pages	4
Volume	4
ISBN (Electronic)	9780128229804
ISBN (Print)	9780128229606
DOIs	https://doi.org/10.1016/B978-0-12-822960-6.00039-9
Publication status	Published - 1 Jan 2022

Keywords

Beta-emitter
Cancer
Radioligand therapy
Theranostics
Tumor environment

Access to Document

10.1016/B978-0-12-822960-6.00039-9

Cite this

@inbook{197f8258981d467a8996584b893d132b,

title = "Potential for a theranostic approach targeting cancer associated fibroblasts",

abstract = "In recent years, targeting cancer associated fibroblasts (CAFs) for efficient therapy approaches has been evaluated. The fibroblast-activating protein (FAP) has received special attention within nuclear medicine approaches due to the development of a successful radiolabeled FAP-inhibitor. This short chapter reviews briefly the background of this approach and gives some insight into potential theranostic applications of the newly developed FAPI ligands.",

keywords = "Beta-emitter, Cancer, Radioligand therapy, Theranostics, Tumor environment",

author = "Patrick Conen and Dautzenberg, {Kai J.} and Mottaghy, {Felix M.}",

year = "2022",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-822960-6.00039-9",

language = "English",

isbn = "9780128229606",

volume = "4",

pages = "353--356",

booktitle = "Nuclear Medicine and Molecular Imaging: Volume 1-4",

publisher = "Elsevier",

address = "United States",

}

TY - CHAP

T1 - Potential for a theranostic approach targeting cancer associated fibroblasts

AU - Conen, Patrick

AU - Dautzenberg, Kai J.

AU - Mottaghy, Felix M.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - In recent years, targeting cancer associated fibroblasts (CAFs) for efficient therapy approaches has been evaluated. The fibroblast-activating protein (FAP) has received special attention within nuclear medicine approaches due to the development of a successful radiolabeled FAP-inhibitor. This short chapter reviews briefly the background of this approach and gives some insight into potential theranostic applications of the newly developed FAPI ligands.

AB - In recent years, targeting cancer associated fibroblasts (CAFs) for efficient therapy approaches has been evaluated. The fibroblast-activating protein (FAP) has received special attention within nuclear medicine approaches due to the development of a successful radiolabeled FAP-inhibitor. This short chapter reviews briefly the background of this approach and gives some insight into potential theranostic applications of the newly developed FAPI ligands.

KW - Beta-emitter

KW - Cancer

KW - Radioligand therapy

KW - Theranostics

KW - Tumor environment

U2 - 10.1016/B978-0-12-822960-6.00039-9

DO - 10.1016/B978-0-12-822960-6.00039-9

M3 - Chapter

SN - 9780128229606

VL - 4

SP - 353

EP - 356

BT - Nuclear Medicine and Molecular Imaging: Volume 1-4

PB - Elsevier

ER -